Skip to content

Study · Not a test of the peptide alone · 2012

5 results

S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice.

Zhang W, Zhang W, Li Z, Hao J, Zhang Z, Liu L, Mao N, Miao J, Zhang L

Pharmacology, biochemistry, and behavior2 Oct 2011Cited by 55 (Europe PMC)

PMID21993310 (opens in a new tab)DOI10.1016/j.pbb.2011.09.012 (opens in a new tab)PepBankPUB-21993310
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Humanin.

  1. 01AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In APPswe/PS1dE9 mice, 3 months of intraperitoneal HNG treatment improved spatial learning deficits versus vehicle.

    In plain wordsIn mice with Alzheimer-like changes, 3 months of a humanin derivative improved spatial learning compared with vehicle.

    Peptide
    Humanin
    Outcome
    IncreaseSpatial learning in APPswe/PS1dE9 mice
    Study

    mousen: not reported in source

    APPswe/PS1dE9 mice, 9 months old
    Comparator
    Vehicle
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    We found that vehicle-treated APPswe/PS1dE9 mice showed impaired spatial learning and memory compared with vehicle- and HNG-treated wild-type mice, while intraperitoneal HNG treatment for 3 months significantly improved spatial learning and memory deficits in APPswe/PS1dE9 mice compared with vehicle control treatment.
    1 context sentence
    Summary · context
    In this study, we employed 9-month-old APPswe/PS1dE9 mice with pre-existing robust amyloid plaque pathology to investigate the effects of chronic HNG treatment on the progression of cognitive dysfunction and Aβ-associated neuropathology.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  2. 02AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In APPswe/PS1dE9 mice, 3 months of intraperitoneal HNG treatment improved spatial memory deficits versus vehicle.

    In plain wordsIn mice with Alzheimer-like changes, 3 months of a humanin derivative improved spatial memory compared with vehicle.

    Peptide
    Humanin
    Outcome
    IncreaseSpatial memory in APPswe/PS1dE9 mice
    Study

    mousen: not reported in source

    APPswe/PS1dE9 mice, 9 months old
    Comparator
    Vehicle
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    We found that vehicle-treated APPswe/PS1dE9 mice showed impaired spatial learning and memory compared with vehicle- and HNG-treated wild-type mice, while intraperitoneal HNG treatment for 3 months significantly improved spatial learning and memory deficits in APPswe/PS1dE9 mice compared with vehicle control treatment.
    1 context sentence
    Summary · context
    In this study, we employed 9-month-old APPswe/PS1dE9 mice with pre-existing robust amyloid plaque pathology to investigate the effects of chronic HNG treatment on the progression of cognitive dysfunction and Aβ-associated neuropathology.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  3. 03AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In APPswe/PS1dE9 mice, HNG treatment reduced cerebral amyloid-beta plaque deposition versus control treatment.

    In plain wordsIn mice with Alzheimer-like changes, a humanin derivative reduced brain amyloid plaques compared with control treatment.

    Peptide
    Humanin
    Outcome
    DecreaseCerebral amyloid-beta plaque deposition
    Study

    mousen: not reported in source

    APPswe/PS1dE9 mice, 9 months old
    Comparator
    Vehicle
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Coincidental with this, HNG treatment significantly reduced cerebral Aβ plaque deposition, insoluble Aβ levels, and neuroinflammatory responses in APPswe/PS1dE9 mice compared with control treatment.
    1 context sentence
    Summary · context
    In this study, we employed 9-month-old APPswe/PS1dE9 mice with pre-existing robust amyloid plaque pathology to investigate the effects of chronic HNG treatment on the progression of cognitive dysfunction and Aβ-associated neuropathology.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  4. 04AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In APPswe/PS1dE9 mice, HNG treatment reduced insoluble amyloid-beta levels versus control treatment.

    In plain wordsIn mice with Alzheimer-like changes, a humanin derivative lowered insoluble amyloid levels compared with control treatment.

    Peptide
    Humanin
    Outcome
    DecreaseInsoluble amyloid-beta levels
    Study

    mousen: not reported in source

    APPswe/PS1dE9 mice, 9 months old
    Comparator
    Vehicle
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Coincidental with this, HNG treatment significantly reduced cerebral Aβ plaque deposition, insoluble Aβ levels, and neuroinflammatory responses in APPswe/PS1dE9 mice compared with control treatment.
    1 context sentence
    Summary · context
    In this study, we employed 9-month-old APPswe/PS1dE9 mice with pre-existing robust amyloid plaque pathology to investigate the effects of chronic HNG treatment on the progression of cognitive dysfunction and Aβ-associated neuropathology.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  5. 05AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In APPswe/PS1dE9 mice, HNG treatment reduced neuroinflammatory responses versus control treatment.

    In plain wordsIn mice with Alzheimer-like changes, a humanin derivative reduced brain inflammation compared with control treatment.

    Peptide
    Humanin
    Outcome
    DecreaseNeuroinflammatory responses
    Study

    mousen: not reported in source

    APPswe/PS1dE9 mice, 9 months old
    Comparator
    Vehicle
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    Coincidental with this, HNG treatment significantly reduced cerebral Aβ plaque deposition, insoluble Aβ levels, and neuroinflammatory responses in APPswe/PS1dE9 mice compared with control treatment.
    1 context sentence
    Summary · context
    In this study, we employed 9-month-old APPswe/PS1dE9 mice with pre-existing robust amyloid plaque pathology to investigate the effects of chronic HNG treatment on the progression of cognitive dysfunction and Aβ-associated neuropathology.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.